Iovance BiotherapeuticsIOVA
IOVA
About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Employees: 557
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
80% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 9 (+4) [Q3]
75% more call options, than puts
Call options by funds: $44.1M | Put options by funds: $25.2M
29% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 83
16% more capital invested
Capital invested by funds: $1.92B [Q2] → $2.22B (+$306M) [Q3]
4% less funds holding
Funds holding: 294 [Q2] → 282 (-12) [Q3]
7.46% less ownership
Funds ownership: 85.33% [Q2] → 77.87% (-7.46%) [Q3]
17% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 47
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.50
29%
upside
Avg. target
$19.75
240%
upside
High target
$32
451%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Piper Sandler Joseph Catanzaro 36% 1-year accuracy 12 / 33 met price target | 29%upside $7.50 | Neutral Maintained | 31 Jan 2025 |
HC Wainwright & Co. Joseph Pantginis 25% 1-year accuracy 102 / 407 met price target | 451%upside $32 | Buy Reiterated | 6 Nov 2024 |
Financial journalist opinion
Based on 8 articles about IOVA published over the past 30 days
Positive
The Motley Fool
5 days ago
What's Wrong With Iovance Biotherapeutics Stock?
It was about a year ago that shares of Iovance Biotherapeutics (IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as a treatment option for patients with unresectable or metastatic melanoma.
Positive
The Motley Fool
6 days ago
Where Will Iovance Biotherapeutics Be in 5 Years?
Iovance Biotherapeutics (IOVA -0.96%), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the company has encountered some success, including a crucial regulatory approval coming down last year, that hasn't been enough to seduce investors.
Positive
The Motley Fool
1 week ago
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
If you're looking for an under-the-radar stock that could deliver enormous gains in a defined time frame, the biopharmaceutical industry has you covered. Hardly a week goes by without clinical trial results or a regulatory decision that produces dramatic market movements.
Negative
The Motley Fool
2 weeks ago
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
Finding the market's highest-growth prospects at any given time isn't terribly tough to do. Finding stocks capable of quintupling in value over the course of the coming five years, however, is a different story.
Neutral
GlobeNewsWire
2 weeks ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on January 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees.
Positive
Seeking Alpha
3 weeks ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Positive
The Motley Fool
3 weeks ago
3 Mid-Cap Stocks That Could Take Off in 2025
Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more modest valuations. Mid-cap stocks represent companies valued at between $2 billion and $10 billion.
Positive
CNBC
3 weeks ago
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Positive
The Motley Fool
1 month ago
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today
Now this is a fine way for a stock to greet the new year. On the back of a glowing analyst recommendation, Iovance Biotherapeutics's (IOVA 5.27%) shares closed Thursday more than 5% higher in price.
Neutral
GlobeNewsWire
1 month ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees.
Charts implemented using Lightweight Charts™